The HLA-E/NKG2A axis plays a role in colorectal cancer (Eugène et al., 2020), multiple myeloma (Yang et al., 2021), and other cancers (Abd Hamid et al., 2019; Borst et al., 2020) and is rapidly gaining attention as a potentially druggable immune checkpoint. Here, KLRC1 is linked to cancer.